Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA Grants Soligenix "Fast Track" Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma
FDA Grants Soligenix "Fast Track" Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma
FDA Grants Soligenix "Fast Track" Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma
Submitted by
admin
on January 7, 2015 - 8:58am
Source:
Yahoo
News Tags:
FDA
Soligenix
fast track
SGX301
cutaneous T-cell lymphoma
Headline:
FDA Grants Soligenix "Fast Track" Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma
Do Not Allow Advertisers to Use My Personal information
